One of the most common questions families ask is: "Which method predicts my child's adult height most accurately?" The short answer: there is no single "best" method — the right one depends on the data you have. This article compares two common clinical methods, Khamis-Roche and Bayley-Pinneau.
This content is educational. Height predictions are reference-based ranges and do not replace a pediatric endocrinology examination.
The core difference: do you need bone age?
The most practical distinction is the input. The Khamis-Roche method works from the child's height, weight and parental heights; it needs no X-ray or bone age. Bayley-Pinneau is based on bone age (a hand-wrist X-ray) and estimates how much of final height is already complete given skeletal maturity.
This one difference drives most decisions: if you don't have bone age, Khamis-Roche is usable; if you do, Bayley-Pinneau adds another perspective.
Khamis-Roche: when it fits
Because it needs no radiation or clinic visit, Khamis-Roche is practical for first screening and at-home tracking. It's useful in the 4–17 range when parental heights are known. Its limit is that it doesn't directly account for maturation (puberty timing); in an early or late developer the estimate can drift.
Bayley-Pinneau: when it fits
Bayley-Pinneau is valuable when bone age has already been measured, because it uses skeletal maturity directly. It reflects the maturation signal especially in suspected early/late puberty. Its limit is that it depends on bone age being read correctly; a wrong bone age means a wrong prediction.
Side by side
| Criterion | Khamis-Roche | Bayley-Pinneau |
|---|---|---|
| Bone age (X-ray) | Not needed | Required |
| Parental height | Required | Not needed |
| Maturation sensitivity | Low | High |
| At-home usability | High | Low (needs X-ray) |
| Typical age range | 4–17 | ~7–18 (by bone age) |
Practical advice: don't trust one method
At Child Growth our approach is to show methods together. Mid-Parental Height gives the genetic ceiling; Khamis-Roche produces a range without bone age; Bayley-Pinneau reflects maturation when bone age exists; percentile projection continues the child's own curve. When the methods converge, confidence rises; when they diverge, that's a signal to discuss with a clinician.
So the question isn't "Khamis-Roche or Bayley-Pinneau?" — it's "with the data I have, what do the methods say together?"
Bottom line
If you don't have bone age, start with Khamis-Roche. If you do, add Bayley-Pinneau and compare the two. In every case, reading several methods together is healthier than trusting a single number. For a definitive assessment, see a pediatric endocrinologist.